8-K: Tharimmune Appoints Vincent LoPriore as Executive Chairman, Replacing Randy Milby

Tharimmune, Inc. announced the appointment of Vincent LoPriore as Executive Chairman of the Board, effective immediately, replacing Randy Milby.

Summary

• On May 9, 2025, Tharimmune, Inc. appointed Vincent LoPriore as Executive Chairman of the Board.
• The appointment was made by the Board of Directors.
• Vincent LoPriore, who was already a director, will assume the role immediately.
• Randy Milby, the previous Chairman of the Board, has been replaced.

Sentiment

Score: 5

Explanation: The announcement is a neutral change in leadership. It doesn't inherently indicate positive or negative sentiment without further context.

Industry Context

Changes in board leadership are common in the biopharmaceutical industry as companies evolve and pursue different strategic directions. The appointment of an Executive Chairman could signal a shift in focus or a desire for more active leadership at Tharimmune.

Comparison to Industry Standards

• Comparing Tharimmune's board structure to similar-sized biotech companies reveals a common trend of having either a separate Chairman and CEO or an Executive Chairman.
• For example, companies like BioNTech and Moderna have different leadership structures, with BioNTech having CEO's and Moderna having a Chairman.
• The effectiveness of each structure depends on the specific company's needs and the skills of the individuals involved.

Management Changes

Stakeholder Impact

• Shareholders may react to the change in leadership depending on their perception of Vincent LoPriore and the reasons behind the change.
• Employees may experience changes in company direction or priorities under the new leadership.

Key Dates

Keywords

Tharimmune, Executive Chairman, Board of Directors, Appointment, Vincent LoPriore, Randy Milby, Corporate Governance